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Abstract
Background: An ad hoc peer-review committee was jointly appointed by Drug Authorities and
Industry in Germany, Austria and Switzerland in 1999/2000 to review the evidence for a causal
relation between phenacetin-free analgesics and nephropathy. The committee found the evidence
as inconclusive and requested a new case-control study of adequate design.
Methods: We performed a population-based case-control study with incident cases of end-stage
renal disease (ESRD) under the age of 50 years and four age and sex-matched neighborhood
controls in 170 dialysis centers (153 in Germany, and 17 in Austria) from January 1, 2001 to
December 31, 2004. Data on lifetime medical history, risk factors, treatment, job exposure and
intake of analgesics were obtained in a standardized face-to-face interview using memory aids to
enhance accuracy. Study design, study performance, analysis plan, and study report were approved
by an independent international advisory committee and by the Drug Authorities involved.
Unconditional logistic regression analyses were performed.
Results: The analysis included 907 cases and 3,622 controls who had never used phenacetin-
containing analgesics in their lifetime. The use of high cumulative lifetime dose (3rd tertile) of
analgesics in the period up to five years before dialysis was not associated with later ESRD.
Adjusted odds ratios with 95% confidence intervals were 0.8 (0.7 – 1.0) and 1.0 (0.8 – 1.3) for ever-
compared with no or low use and high use compared with low use, respectively. The same results
were found for all analgesics and for mono-, and combination preparations with and without
caffeine. No increased risk was shown in analyses stratifying for dose and duration. Dose-response
analyses showed that analgesic use was not associated with an increased risk for ESRD up to 3.5
kg cumulative lifetime dose (98 % of the cases with ESRD). While the large subgroup of users with
a lifetime dose up to 0.5 kg (278 cases and 1365 controls) showed a significantly decreased risk, a
tiny subgroup of extreme users with over 3.5 kg lifetime use (19 cases and 11 controls) showed a
significant risk increase. The detailed evaluation of 22 cases and 19 controls with over 2.5 kg lifetime
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use recommended by the regulatory advisors showed an impressive excess of other conditions
than analgesics triggering the evolution of ESRD in cases compared with controls.
Conclusion: We found no clinically meaningful evidence for an increased risk of ESRD associated
with use of phenacetin-free analgesics in single or combined formulation. The apparent risk
increase shown in a small subgroup with extreme lifetime dose of analgesics is most likely an
indirect, non-causal association. This hypothesis, however, cannot be confirmed or refuted within
our case-control study. Overall, our results lend support to the mounting evidence that
phenacetin-free analgesics do not induce ESRD and that the notion of "analgesic nephropathy"
needs to be re-evaluated.
Background
The publications by Spühler et al. [1], Dubach et al. [2]
and Zollinger [3] five decades ago on the relationship
between kidney damage and phenacetin ultimately led to
the recognition of a causal relation between the two. This
was supported by the experience in the Swedish factory
Husqvarna [4]. Many epidemiological studies and review
papers contributed to this view. In the 1990ies, many
nephrologists by extension suspected that non-phenace-
tin analgesic combinations, especially those containing
paracetamol and aspirin (plus caffeine) might also cause
end-stage renal disease (ESRD; cf. reviews [5-7]), and
introduced the term "analgesic nephropathy." Since data
were scarce, this hypothesis engendered some controversy
[8,9], and ultimately led the regulatory authorities of Ger-
many, Austria and Switzerland to initiate a scientific re-
evaluation. A peer review committee of scientists, jointly
selected by the regulatory authorities and the pharmaceu-
tical industry, was asked to critically review the data on the
relationship between non-phenacetin combined analge-
sics and nephropathy on the basis of a systematic litera-
ture review. The committee's three main conclusions were
that (1) existing studies show no justified suspicion of any
increased risk of ESRD for phenacetin-free analgesic com-
binations, (2) there is insufficient evidence to associate
non-phenacetin combined analgesics with nephropathy
and (3) new studies should be done to provide appropri-
ate data to resolve the issue [10].
In their initial deliberations on such a study, the Scientific
Board recommended that the outcome of interest be
ESRD (defined as incident dialysis), and that the exposure
of interest be all phenacetin-free analgesics, including
NSAIDs), regardless of the formulation. The board was
aware that the analysis would address several subgroups,
including analgesics co-formulated with caffeine. The
design efforts resulted in a detailed, published study pro-
tocol, confirmed and approved by the regulatory authori-
ties [11].
The primary objective of this study was to determine the
association between the lifetime use of all phenacetin-free
analgesics and the occurrence of ESRD. ESRD risk was to
be evaluated for several mono substances ("Monos"),
fixed combination analgesics ("Combis"), by cumulative
lifetime dose, duration, and dose by duration of use of
phenacetin-free analgesics. This paper presents the main
results of the international case-control study on the asso-
ciation of phenacetin-free analgesics and ESRD.
Methods
The study was designed as a population-based case-con-
trol study to investigate the risk of phenacetin-free analge-
sics with regard to the occurrence of ESRD in Germany
and Austria between January, 2001 and December, 2004.
The study protocol was reviewed and agreed to by the Sci-
entific Advisory Committee, was accepted by the regula-
tory authorities of Germany, Austria, and Switzerland,
and was reviewed and approved by the Kidney Founda-
tion of Germany. It was supported by the three Nephro-
logical Societies in Germany and the Nephrological
Association of Austria, published in BMC Nephrology
[11], shown on an open-access website [12], registered as
clinical study in the FDA website (Protocol Registration
Receipt NCT00302835) [13], and approved as a study
protocol by the Lancet.
Cases were recruited from 170 dialysis centers and were
defined as patients with end-stage renal disease (ESRD)
newly admitted to a chronic dialysis program (incident
dialysis) and aged up to 50 years. Rapid case ascertain-
ment systems were used to identify all eligible cases. Cases
were excluded if they had acute or recurrent renal failure,
were out of age range, died before the interview could be
done, were in poor physical or mental condition, or
refused informed consent to participate in the study. Four
neighborhood controls were randomly selected from the
same geographic regions as the cases and were matched by
age (5-year age group) and sex. Cases and controls docu-
mented their willingness to participate in the study by
signing an informed consent form.
All study participants completed a standardized in-person
interview, during which a trained interviewer collected
information on lifetime use of analgesics documented by
brand name as well as details and dates of lifetime use, onBMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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co-morbidity (renal, circulatory, metabolic, psychiatric,
other medical conditions, headache or other painful con-
ditions), treatment history (treatments with potential
relation to outcome and risk factors), job exposure (occu-
pation & industrial branch; exposure in selected occupa-
tional categories; exposure to groups of certain chemicals
and minerals), and other demographic data such as age,
sex, area of residence, and health care contacts. Partici-
pants were shown a book of color photographs and other
descriptions of analgesics (mixed with other common
drugs to blind the interviewee) marketed from the 1950s,
organized by brand, name, dose, and the period during
which the drugs were available to elicit an accurate life-
time history of analgesic use. Training and re-training of
interviewers as well as briefing and re-briefing of study
centers were standard quality control measures. Detailed
logbooks were maintained in all participating dialysis
centers for all new dialysis patients. The procedures to
minimize potential bias included complete coverage of
new dialysis patients (to address selection bias), use of
index dates in the analysis (reverse causality bias), blind-
ing of interviewers to the main research question (inter-
viewer bias), and the restriction to phenacetin-free
analgesics and adjustment for co-variables to reduce con-
founding. The data were collected locally, transferred to
the central Data Management and Coordination Centre
Berlin at the ZEG Berlin, and then to EPES Berlin for data
analysis.
The SAC approved a detailed analysis plan for the "core
analyses" which included a review of center performance
and response rates. Frequency distributions of exposure
with analgesics by case/control status and by index dates
were calculated.
A fixed reference group defined as individuals who had
been exposed to less than one table or unit dose of any
phenacetin-free analgesic compound per month across all
12-months periods in their lifetimes was used for all anal-
yses. This group is comprised of all participants who indi-
cated no or very low use of analgesics, and is called "low
use" in text and tables. This strategy was adopted to
account for the potential differential recall of trivial use in
cases and controls, based on the notion that controls may
have poorer recall of irregular and low use than cases
despite all standard memory aids used (cf. protocol pub-
lished in this journal [11]). The decision was approved by
the SAC after discussion of intermediate analyses and
became integral part of the analysis plan. All persons sus-
pected to have ever taken phenacetin in their lifetime were
excluded.
Several index dates were defined and examined to deter-
mine the most appropriate lag time between exposure to
analgesics and the start of dialysis. The decision was made
that exposures in the 5 years prior to start of dialysis
should not be used in analyses concerning ESRD risk [11]
because analgesic use may have been initiated due to
incipient kidney disease during that time.
Logistic regression analyses were used to estimate the
association between ESRD and analgesic exposure. Crude
and adjusted odds ratios with 95% confidence interval
were calculated. The decision was made a priori to use
unmatched analysis if the risk estimates of matched anal-
ysis did not materially differ [11]. This is because less
information is lost in unmatched analyses and these are
therefore better suited for subgroup analyses.
Many possible risk factors for ESRD (cf. Table 1) were
assessed for confounding. Logistic regression with back-
wards elimination was used to define the adjustment var-
iables for the analytic model. The final set of adjustment
variables were age (5-year group), sex (male, female),
country (Germany, Austria), first degree family history of
chronic renal diseases (yes, no), and self-reported expo-
sure with welding/soldering fumes, solvents (yes, no),
and education(over/under 10 years). Following the rec-
ommendation of the study's statistical advisory commit-
tee, co-variables assumed to be intermediates in the causal
pathway of ESRD -such as hypertension or diabetes – were
excluded from the list of possible confounders for the
final analysis to avoid over-adjustment.
The analyses focused on the association between high
cumulative lifetime dose (grams) and ESRD across various
subgroups of analgesic formulations. The primary com-
parison was that of the top tertile of cumulative lifetime
dose with no or very low use for users of all phenacetin-
free analgesics and for users of analgesic subgroups.
Due to the small numbers in many analgesic formulation
subgroups, the SAC recommended using only a minimum
of adjustment variables and to refrain from calculating or
reporting odds ratios if any of the cells for a comparison
contained less than 10 subjects. Doses per duration of use
were analyzed as well as dose-response analyses. More
detailed dose-response analyses will be published at a
later time in a methodology paper. Because matched and
unmatched analyses showed virtually identical results, the
SAC decided that this publication should show the results
of unmatched analyses.
All statistical analyses were performed with the commer-
cial statistical software Stata 8.1.
Results
Description of cases and controls
Of 1,831 cases identified, 1,305 met the study entry crite-
ria, 978 were interviewed, and 907 phenacetin-free casesBMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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Table 1: Characteristics of ESRD cases and controls at study entry.
Cases1 N = 907 Controls1 N = 3622 P
N%N%
Age (years) < 40 424 46.8 1644 45.4
40–50 483 53.2 1978 54.6 .46
Gender Male 585 64.5 2333 64.4
Female 322 35.5 1289 35.6 .96
Country Germany 726 80.0 2890 79.8
Austria 181 20.0 732 20.2 .87
Education (years) - 10 603 66.5 1998 55.2
> 10 304 33.5 1624 44.8 < .001
Smoking Never 340 37.5 1528 42.2
Current 277 30.5 694 19.2
Ex-smoker 290 32.0 1400 38.6 < .001
Alcohol Seldom 757 83.5 1857 51.3
Often 150 16.5 1765 48.7 . < .001
History of conditions, diseases
Diabetes mellitus No 748 82.5 3572 98.6
Yes 159 17.5 50 1.4 < .001
Hypertension No 134 14.8 3253 89.8
Yes 773 85.2 369 10.2 < .001
Renal diseases No 25 2.8 3448 95.2
Yes 882 97.2 174 4.8 < .001
Urinary tract infections No 802 88.4 3478 96.0
Yes 105 11.6 144 4.0 < .001
Family history: chronic renal disease No 697 76.9 3425 94.6
Yes 210 23.1 197 5.4 < .001
Migraine No 766 84.5 3250 89.7
Yes 141 15.5 372 10.3 < .001
Headache No 656 72.3 2728 75.3
Yes 251 27.7 894 24.7 .06
Menstruation problems No 233 25.7 937 25.9
Yes 89 9.8 352 9.7
n.a. 585 64.5 2333 64.4 .99
Arthritic complaints No 828 91.3 3418 94.4
Yes 79 8.7 204 5.6 < .001
Chronic back pain No 710 78.3 2866 79.1
Yes 197 21.7 756 20.9 .58
Psychological/neurological problems No 829 91.4 3397 93.8
Yes 78 8.6 225 6.2 .01
History of treatment
Anti-rheumatic treatment No 892 98.4 3600 99.4
Yes 15 1.6 22 0.6 < .01
Immuno-suppressive therapy No 866 95.5 3617 99.9
Yes 41 4.5 5 0.1 < .001
Drug treatment against cancer No 889 98.0 3605 99.5
Yes 18 2.0 17 0.5 < .001
Long-term treatment with antibiotics No 854 94.2 3526 97.4
Yes 53 5.8 96 2.7 .000
Complaints (subjectively compared with 
other persons in the same age span)
Gastrointestinal problems No, rare 577 63.6 2550 70.4
Similar/more 330 36.4 1072 29.6 < .001
Cardiovascular problems No, rare 610 67.3 3041 84.0
Similar/more 297 32.7 581 16.0 < .001
Vomiting No, rare 612 67.5 3187 88.0
Similar/more 295 32.5 435 12.0 < .001
Depression No, rare 719 79.3 3172 87.6
Similar/more 188 20.7 450 12.4 < .001BMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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were included in the analysis. The reasons for exclusion
are shown in Figure 1. Similarly, of 6,587 potential neigh-
borhood -controls, 6.236 were eligible, 3,892 were inter-
viewed after 1,878 were excluded due to refusal to
participate and 466 for undeclared reasons, and 3,622
controls without history of phenacetin use finally entered
the analysis (Fig. 1). There were 71 cases and 270 controls
with reasonable evidence for past phenacetin use mainly
during childhood or early youth who were excluded from
analysis. In terms of the study protocol, response rates of
74.9% for cases (978 of 1,305 eligibles) and 62.4 %
(3,892 interviewed of 6,236 eligible) were considered
acceptable. No important heterogeneity was observed for
response rates across subgroups of age, gender, or case/
control status (data not shown).
Table 1 provides an overview of baseline characteristics
for all cases and their controls. As expected from the
matching process, there was no difference between cases
and controls with regard to age, sex, and country. Com-
pared with cases, controls had a proportionately higher
educational level (defined as more than 10 years of
school), smoked less, but consumed more alcohol. Cases
more frequently reported conditions suspected to play a
role in ESRD development such as diabetes, hypertension,
renal diseases, urinary tract infections, and a first-degree
family history of chronic renal conditions. There was a
higher proportion of painful conditions such as headache,
migraine, chronic back or arthritic pain as well as use of
specific medications (anti-rheumatic, immune-suppres-
sive, or long-term therapy with antibiotics) among cases
than among controls. Relative to their age group, controls
more frequently voiced minor subjective physical and
psychological complaints than did cases, which were
more prone to major complaints (Table 1). Cases more
often reported worksite exposure to heavy metals, other
metal dust (such as aluminum, copper, chromium, tin),
certain silicates (such as sand, cement, coal, rock, grain
dust), solvents (such as varnish & paints, glue, crude oil,
fuel, diesel, toluene), and welding and soldering fumes.
These descriptive differences were taken into account for
the determination of the adjustment factors for the main
analysis.
The most frequently named underlying conditions lead-
ing to ESRD were glomerulonephritis (34.5%), pyelone-
phritis/interstitial nephritis (7.6%), polycystic kidney
disease (12%), and diabetic nephropathy (15.8%), Other
diseases such as lupus erythematosus, tuberculosis, vascu-
lopathy, infarction, alport syndrome, and amyloid neph-
rosis were named in 18.5% of cases. The cause of kidney
disease was unclear for the treating physician in 10.9%.
"Analgesic nephropathy" was considered to be the cause
of ESRD in only 5 of 907 cases (0.6%).
Anxiety No, rare 762 84.0 3259 90.0
Similar/more 145 16.0 363 10.0 < .001
Sleeplessness No, rare 542 59.8 2821 77.9
Similar/more 365 40.2 801 22.1 < .001
Fatigue No, rare 333 36.7 2490 68.8
Similar/more 574 63.3 1132 31.2 < .001
Irritability No, rare 505 55.7 2376 65.6
Similar/more 402 44.3 1246 34.4 < .001
Stress No, rare 459 50.6 1713 47.3
Similar/more 448 49.4 1909 52.7 < .001
Eating problems No, rare 752 82.9 3368 93.0
Similar/more 155 17.1 254 7.0 < .001
History of exposures at work site
Heavy metal No 750 82.7 3216 88.8
Yes 157 17.3 406 11.2 < .001
Other metal dust No 765 84.3 3240 89.5
Yes 142 15.7 382 10.5 < .001
Special silicates2 No 847 93.4 3431 94.7
Yes 60 6.6 191 5.3 .11
Other silicates3 No 796 87.8 3375 93.2
Yes 111 12.2 247 6.8 < .001
Solvents No 751 82.8 3188 88.0
Yes 156 17.2 434 12.0 < .001
Welding & soldering fumes No 797 87.9 3384 93.4
Yes 110 12.1 238 6.6 < .001
1 Deviations from the total number of cases and controls are due to missing information
2 e.g. quartz, silicon dioxide, fibre glass, silicone
3 e.g. sand, cement, coal, grain dust
Table 1: Characteristics of ESRD cases and controls at study entry. (Continued)BMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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Overall risk of ESRD, ever use, and cumulative lifetime 
dose
The main research question defined in the study protocol
addressed the risk of ever use of phenacetin-free analgesics
at index date 3 (the status 5 years before first dialysis)
compared with no or low use of such substances. This
standard reference group of individuals with no or very
low use was defined as including those with exposure to
less than one tablet or unit of any phenacetin-free analge-
sic compound per month across all 12-months periods of
the participant's lifetime. The adjusted odds ratio (OR) for
this analysis is 0.84, 95% confidence interval (CI): 0.71 to
0.98. The crude and adjusted risk estimates were virtually
identical.
Flow chart: inclusion and exclusion of possible cases and controls Figure 1
Flow chart: inclusion and exclusion of possible cases and controls.
 
Cases identified
(n = 1,831)
Acute Dialysis (n= 71)
Identified after study period (n= 119)
Re-Dialysis (n= 92)
Dialysis start not in study period (n= 49)
Death before interview (n= 30)
Poor physical/mental status (n= 142)
Out of age range (n= 18)
Other reasons (n= 5)
Eligible Cases
(n = 1,305)
Interview rejected (n= 270) Other reasons (n= 57)
Interviewed Cases
(n = 978)
Cases without phenacetin history
(n = 907)
A. CASES
 
 
_____________________________________________________________________ 
 
 
Controls identified
(n = 6,587)
Poor physical/mental status (n= 154)
Out or age range/other reasons (n= 204)
Eligible Controls
(n = 6,236)
Interview rejected (n= 1,878)
Interviewed Controls
(n = 3,892)
Controls without phenacetin history
(n = 3,622)
B. CONTROLS
Other undeclared reasons (n= 466)
 BMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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The association between cumulative lifetime dose of anal-
gesics and ESRD is shown in Table 2. The sub-categories
of lifetime analgesic use are not mutually exclusive. The
use of higher cumulative lifetime dose (tertile 3) of anal-
gesics up to five years before dialysis was not associated
with later ESRD either for all phenacetin-free analgesics
together (All), or for analgesics with a single substance
(monos), or for analgesics with multiple components
(combis). Most risk estimates were below unity (1.0). Risk
estimates calculated for medium lifetime doses (= tertile 2
and 1 combined) compared with the reference group of
low use showed significantly decreased estimates. The
adjusted comparison of high users of all phenacetin-free
analgesics together with no or very low use showed a risk
of 1.02 (95% CI: 0.81 to 1.28), the same estimate for all
mono-analgesics was 0.98 (95% CI: 0.77 to 1.24). This
estimate did not change when aspirin and paracetamol
were excluded from the mono-preparations (OR 0.90;
95% CI: 0.61 to 1.31.). The overall estimate for the ESRD
risk of high use of any combination analgesic compared
with the reference group of no or very low use was 1.05
(95% CI: 0.77 to 1.44). Combination analgesics with or
without paracetamol showed risk estimates in the same
order of magnitude (cf. Table 2). Finally, no differences
were found for the comparison between high versus low
use when examining compounds with and without caf-
feine in this younger population with no prior use of
phenacetin. We observed no evidence of an increased or
different risk of ESRD associated with analgesic use (all
analgesics, single substances, or combination products)
with regard to the underlying disease of ESRD. The risk
varied around unity across all disease subgroups contain-
ing sufficient numbers for analysis. These data will be pre-
sented at a later time in a clinical publication.
Combined association of dose and duration
The relationship of analgesic dose and duration of use and
their potential impact on ESRD development was exam-
ined extensively. Table 3 shows the analyses for all analge-
sics, mono-substance and combination preparations
separately for lower and higher user of analgesics and for
shorter and longer durations, where the cut-off points for
each class are based on the respective median value found
in controls. Although no significant increase is found, the
table indicates that there may be a weak positive associa-
tion with higher doses of analgesics used for shorter dura-
Table 2: Lifetime dose of analgesic use1 and risk of ESRD.
Exposure Range grams Cases Controls Adjusted OR2 (95% CI)
All phenacetin-free analgesics Low 546 2030 1.0 (referent)
Tertile 1,2 < 217 213 1067 0.75 (0.63–0.90)
Tertile 3 > = 217 148 525 1.02 (0.81–1.28)
MONOS (single substance) Tertile 1,2 < 185 185 975 0.72 (0.59–0.87)
All monos Tertile 3 > = 185 129 479 0.98 (0.77–1.24)
Other 47 138 1.21 (0.84–1.74)
All- no ASA & paracetamol Tertile 1,2 < 65 62 322 0.70 (0.51–0.94)
Tertile 3 > = 65 43 159 0.90 (0.61–1.31)
Other 256 1111 0.87 (0.73–1.03)
COMBIS (combined products)
All combis together Tertile 1,2 < 91 93 469 0.73 (0.56–0.93)
Tertile 3 > = 91 75 235 1.05 (0.77–1.44)
Other 193 888 0.84 (0.69–1.02)
All combis with paracetamol Tertile 1,2 < 83 87 401 0,78 (0.59–1.01)
Tertile 3 > = 83 57 197 0.95 (0.67–1.35)
Other 217 994 0.84 (0.70–1.01)
All combis without paracetamol Tertile 1,2 < 68 27 131 0.75 (0.49–1.16)
Tertile 3 > = 68 26 64 1.41 (0.85–2.35)
Other 308 1397 0.82 (0.69–0.97)
All combis with caffeine Tertile 1,2 < 87 67 342 0.70 (0.52–0.94)
Tertile 3 > = 87 55 169 1.01 (0.71–1.44)
Other 239 1081 0.85 (0.71–1.02)
All combis without caffeine Tertile 1,2 < 57 44 237 0.69 (0.49–0.99)
Tertile 3 > = 57 37 118 1.15 (0.76–1.73)
Other 280 1237 0.84 (0.70–0.99)
1 Lifetime dose of analgesic use: medium = tertile1 and 2; high = tertile 3 vs. referent = no or very low analgesic use (exposure to less than one 
tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime) at index date 3 (5 
years before first dialysis). The category "other" means: other analgesics than those considered in the specific sub-analysis. The numbers don't add 
up because participants were classified into the category "other" analgesic, which is not exclusive.
2 Unmatched analysis; adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Adjustment for age group, sex, country, family history 
chronic renal diseases, exposure with welding/soldering fumes, solvents, and educationBMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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tion (left lower corner of Table 3) On the other hand,
lower user of analgesics for longer durations (upper right
corner) showed statistically significant lower risks for 2 of
3 analgesic types analyzed. Finally, lower use and shorter
duration showed a statistically significant inverse associa-
tion for all 3 analgesic types. There was an inverse associ-
ation (not statistically significant) for 2 of 3 types for
higher dose and longer duration of use. The numbers were
too small for stable risk estimates of formulation sub-
groups.
Adjustment for confounding by other analgesic 
formulations
In order to account for overlapping of the use of different
analgesic formulation during the participant's lifetime, all
other analgesic subgroups were taken into the equation
(Table 4). No significant association with ESRD was
shown for any formulations containing ASA, paracetamol
or containing neither of these two substances, i.e. the
ESRD risk associated with high use (3rd tertile of cumu-
lated lifetime use) vs. low use varied around unity.
Dose-response
The cumulative lifetime dose of analgesics (in grams) was
stratified in eight sub-categories in steps of 500 grams up
to 3.5 kg in order to show the risk distribution up to the
uppermost dose groups (Table 5). There was no increased
risk for ESRD up to 3.5 kg cumulative lifetime dose (98 %
of the cases with ESRD). A significantly increased risk was
found for the tiny subgroup of upper-most lifetime dose
of more than 3.5 kg in this young age group (19 cases and
11 controls, 2% of all cases and 0.3% of all controls).
Conversely, the risk was significantly reduced for the large
subgroup of user with a lifetime dose up to 0.5 kg. In a sec-
ond approach we examined the risk of ESRD contributed
per gram at various levels of use compared with "no or
Table 4: Risk of ESRD and cumulative lifetime dose of Paracetamol, ASA, and substances containing neither ASA nor Paracetamol 
(mainly Ibuprofen) in any combination (mono- or combi) versus low use1
Dose (tertiles) Range (grams) Cases Controls OR (95% CI)
No/rare use 546 2030 1.0 (referent)
ASA I < 50 96 431 0.96 (0.60–1.54)
II 50–162 77 443 0.77 (0.46–1.27)
III 163+ 114 432 1.07 (0.64–1.77)
Paracetamol I < 17 61 297 n.d.2
II 17–74 65 304 0.95 (0.63–1.42)
III 75+ 77 296 1.11 (0.74–1.67)
Other I < 12 38 208 0.66 (0.41–1.08)
II 12–73 47 215 0.79 (0.50–1.23)
III 74+ 63 209 n.d.2
1 Standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-
months periods in the observed lifetime. Unmatched analysis; Adjustment for family history, soldering fumes, solvents, education, and for age, sex, 
country. Adjustment for confounding by all other analgesic combinations.
2 dropped due to collinearity
n.d. = no data
Table 3: Dose and duration of analgesic use and risk of ESRD: All analgesics.
Short duration Long Duration
Cases/controls OR (95% CI)* Cases/controls OR (95% CI) *
Low dose All analgesics 123/580 0.78 (0.63–0.97) 36/216 0.62 (0.43–0.89)
All monos together1 106/529 0.74 (0.59–0.93) 31/200 0.57 (0.39–0.85)
All combis together2 49/264 0.69 (0.50–0.95) 19/84 0.84 (0.51–1.40)
High Dose All analgesics 70/214 1.21 (0.91–1.61) 132/582 0.84(0.67–1.05)
All monos together1 60/194 1.14 (0.84–1.55) 117/531 0.82(0.65–1.03)
All combis together2 29/88 1.22 (0.79–1.88) 71/268 0.99 (0.74–1.33)
1 Cases and controls that never used mono-analgesics were not shown in this table (47 cases, 138 controls for the group "all monos"
2 Cases and controls that never used combination-analgesics were not shown in this table (193 cases, 888 controls for the group "all combis"
Unmatched analysis; index date 3 (5 years before start of dialysis); adjusted odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for 
age, sex, country.
The cut-off point for higher/lower use and shorter/longer duration is the respective median found in controls; compared with the standard 
reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months 
periods in the observed lifetime) as referent (= 1.0): 546 cases and 2030 controls.BMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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very low use". This essentially confirms the above men-
tioned results, as each gram of use is associated with low-
ered risk for the group below 0.6 kg lifetime analgesics
consumption, it is associated with no risk in the group up
to 4.6 kg, and only in the group over 4.6 kg is there a sig-
nificantly increased risk of ESRD per dose (table not
shown). This threshold applies to 12 cases (= 1.3% of all
cases) and 3 controls (= 0.08%) in this study. None of
these were categorized as analgesic nephropathy by their
treating physicians.
Description of pattern associated with uppermost 
cumulative lifetime use of analgesics
A detailed review of the characteristics of the 22 cases (2.4
% of all cases) and 19 controls (0.5 % of all controls) who
reported at least 2.5 kg or more cumulative lifetime dose
of analgesics was conducted. This cut-off point was rec-
ommended by the SAC and approved by the German
Drug Authority. No difference in the reason for analgesic
use for the cases and controls in this subgroup, or in their
subjective complaints was determined. However, condi-
tions associated with the causal pathway of ESRD such as
hypertension, diabetes, gout, arterial diseases (cardiac,
cerebral, peripheral), renal diseases, other serious diseases
or operations, and family history of chronic renal diseases
were much more prevalent in cases than in controls with
upper-most, extreme use of analgesics. Cumulatively,
70% of the 22 cases had three and more of these seven
conditions and 70% of the 19 controls had 0–1 of these
conditions related to the evolution of ESRD (Table 6).
Discussion
The objective of this study was the investigation of the
effect of lifetime use of phenacetin-free analgesics on
ESRD occurrence in a younger population. The restriction
to a study group below the age of 50 was a prerequisite for
the effective exclusion of phenacetin use, and we believe
that this is the first study to completely avoid phenacetin
contamination in the assessment of ESRD associated with
analgesic uses. The results suggest that there is no associa-
tion between ESRD and analgesic use in general, nor with
the use of specific analgesics or combinations with or
without additional caffeine in the age group below 50
years.
The direct comparison of baseline users of no or very low
lifetime analgesic doses with the tertile distributions of
lifetime doses in grams of the user group shows no
increased ESRD risk associated with phenacetin-free anal-
gesics in the highest tertile. Instead, there was a signifi-
cantly reduced risk ESRD for the lower two tertiles for all
analgesics, mono-preparations, and combination prod-
ucts. No clinically relevant increase of ESRD risk with
increasing dose was found in an analysis of the effect of
ASA, paracetamol, and other ingredients with full adjust-
ment including other analgesic combinations. Users of
lower doses of analgesics showed a decreased risk of ESRD
independent of duration of use (Table 3). The group of
users of high lifetime doses showed a non-significant ten-
dency for higher risks when these substances were taken
within a shorter period. We cannot draw any strong con-
clusions from the findings related to the combined associ-
ations of dose and duration of analgesic use.
The detailed examination of dose-response distributions
showed no association or significantly reduced risks of
ESRD for almost all levels of analgesic use. However, a
tiny group of cases and controls showed a significantly
increased risk associated with a dose over 3.5 kg in the
dose-stratified analyses. This was found to significantly
increase around a dose of 4–5 kg lifetime use of analgesics
Table 6: Number of factors related to development of ESRD in 
individual cases and controls with high-end intake of analgesics 
(see table before).
Number of 
conditions1
Cases n = 22 Controls n = 19
n% n %
6 14 . 5 0 0
5 41 8 . 2 0 0
4 62 7 . 3 0 0
3 52 2 . 7 0 0
2 5 2 2 . 763 1 . 6
1 1 4.5 7 36.8
0 00 63 1 . 6
1 The following seven conditions were considered for this table: 
Arterial problems (coronary, brain, peripheral), hypertension, 
diabetes mellitus, gout, renal diseases, other serious diseases/
operations, and family history of chronic renal diseases (first degree 
relatives)
Table 5: Adjusted relative risk of ESRD by increasing cumulative 
lifetime dose of analgesic use (all analgesics together).
Grams Cases Controls OR (95% CI)
Low use 546 2030 1.00 (referent)
-500 278 1365 0.75 (0.64–0.88)
501–1000 41 133 1.10 (0.77–1.59)
1001–1500 10 47 0.76 (0.38–1.52)
1501–2000 6 19 1.03 (0.40–2.62)
2001–2500 4 9 1.50 (0.48–4.74)
2501–3000 3 8 1.35 (0.37–4.94)
3001 + 19 11 6.02 (2.83–12.81)
Categorical modeling for dose-response analyses. Odds ratios and 
95% confidence intervals. Analysis based on index date 3 (5 years 
before start of dialysis), adjusted for age, sex, country. ORs were not 
calculated if the frequency in any group was less than 10 per cell: no 
data (n.d.) in the table. Standard reference group of low use is defined 
as exposure to less than one tablet or unit dose of any phenacetin-free 
analgesic compound per month across all 12-months periods in the 
observed lifetime.BMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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in the continuous dose analyses. This level of use corre-
sponds to a daily consumption of 200 to 400 grams of
analgesic over a 30-year period. Because the numbers in
this subgroup were too low for estimation, a detailed
description was prepared for this upper-most dose group
(22 cases and 19 controls). The main distinction between
cases and controls were the much higher prevalence of fac-
tors closely associated with later development of ESRD
among the cases, so that we interpret this group as being
defined by their high-risk status rather than by their use of
analgesics which is incidental to their prior health condi-
tion. The same conclusion was reached by an external
expert in nephrology (Prof. Michielsen) who was asked by
the Scientific Advisory Committee of the study and by the
German Drug Authority to individually evaluate the like-
lihood that high analgesic use in these cases is is the cause
of their ESRD. Prof. Michielsen expressed in his report
that the individual assessment of lifetime users of 2.5 kg
analgesic user indicated:1)There is no evidence of classical
analgesic nephropathy, and 2) that there is no indication
that analgesic use influenced the evolution to ESRD in this
small group of extremely high users (cf. full assessment
report at the SAN website [12]).
Strengths and weaknesses of the study
The two important advantages of this study are the use of
a 5-year lag-time across all analyses on analgesic exposure
and ESRD risk and the presumably complete exclusion of
past use of phenacetin. The 5-year lag time has previously
been used in only two [14,15] studies. It addresses the
issue of temporality and reduces the risk of showing esti-
mates based on analgesic use prompted by an incipient
renal condition rather than on the occurrence of a renal
condition following a period of analgesic use (reverse cau-
sality bias). To our knowledge, no previous study has
eliminated phenacetin use from its population to the
extent this study has, and we consider this a condition
sine qua non for the estimation of ESRD risk associated
with the currently available analgesics.
Every effort was made to minimize recall and information
bias by using face-to-face interviews with a set of aids and
procedures to jog memory, check the plausibility of
recalled analgesic use, and to provide similar conditions
for cases and controls. Selection bias is addressed in the
community-based approach of this case-control study.
Logbooks were maintained in dialysis centers to assure
complete coverage. Nonetheless, and although compara-
ble with other studies in this area, a non-response rate of
around 30% leaves some possibility for bias. It is reassur-
ing that the information available on non-responders did
not differ from the information for those included in the
study. Finally, the study suffers the limitations of all
observational studies in that the participation of cases
may be very much determined by intentions of the treat-
ing physician who invited patients, while the situation
could differ for controls. Differences in reporting behavior
between cases and controls can never be entirely excluded,
and controls who consumed large amounts of analgesics
may have a poor health-related quality of life which pre-
vents them from volunteering for such a study.
The age limit of 50 years is strength of the study because it
largely eliminates phenacetin users from this population,
but it may also restrict the generalizability of the findings.
However, this study feature was considered an essential
safeguard against confounding by phenacetin use. Relia-
ble results for the risk of ESRD and analgesic use in the
population aged 50 to 70 years, for example, could be
obtained only in the decades when phenacetin users had
slowly depleted. Even then, the much higher potential of
serious confounding and bias in the higher age group
would make it difficult to interpret an association
because, if any association is found, it is likely to be small.
Although the possibility that some persons might not
have sufficient time to accumulate a harmful lifetime dose
up to the age of 50 years, we consider the evidence of no
clinically important association between analgesic use
and ESRD provided by this study to be the best currently
available. Therefore, and in the absence of other reliable
evidence, the results of this study most likely also apply to
higher age groups.
The debate on analgesic use and nephropathy has gone on
for decades and is not yet concluded [16]. Many earlier
studies which did not exclude past phenacetin use found
a significant association between analgesic use and
chronic renal failure/ESRD with relative risk increases
ranging from 2- to 8-fold [17-22]. Other studies observed
no or no clearly increased risk or variations among formu-
lations [14,15,23,24] or else were inconclusive [25,26].
Fored et al. (2003) [15] did not rule out that the associa-
tions found in their study might be due to bias, i.e. that
the use of analgesics was triggered by conditions associ-
ated with the renal disease.
Recently, Mihatsch et al. (2006) [27], conducted an exact
replication of the benchmark autopsy studies on analgesic
nephropathy which he performed 1978–80 in Basel [28].
The author wrote: "The last and single autopsy case of
proven classic analgesic nephropathy detected only with
the present sophisticated histological study at the end of
the year 2000 can thus be taken as further evidence that
this type of chronic renal disease was due to nothing but
phenacetin-containing mixed analgesics. Some 20 years
after removal of phenacetin from the market classic anal-
gesic nephropathy is all but disappearing and will no
longer be a health hazard in the 21st century." [27]. TheBMC Nephrology 2007, 8:15 http://www.biomedcentral.com/1471-2369/8/15
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results of the present study on a population of individuals
with no prior phenacetin use supports this finding.
The present study adds to the available data characterizing
the association of ESRD risk and lifetime consumption of
analgesics applying advanced methods. Our data show no
significant association between ESRD and analgesic use in
general or for the use of specific analgesics or combina-
tions with or without additional caffeine. The descriptive
analysis of a small highly exposed subgroup indicates that
their very high cumulative lifetime use of analgesics is
based on a pattern of chronic, painful ill health and does
not constitute a causal association with ESRD. However,
further research on extreme users of analgesics is recom-
mended.
Conclusion
We found no clinically meaningful evidence for an
increased risk of ESRD associated with use of phenacetin-
free analgesics in single or combined formulation. The
apparent risk increase shown in a small subgroup with
extreme lifetime dose of analgesics is most likely an indi-
rect, non-causal association. This hypothesis, however,
cannot be confirmed or refuted within our case-control
study. Overall, our results lend support to the mounting
evidence that phenacetin-free analgesics do not induce
ESRD and that the notion of "analgesic nephropathy"
needs to be re-evaluated.
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